In addition, recent studies have shown significant efficacy of HER2-targeted agents for advanced breast cancer patients with low HER2 expression (IHC score of 1+ or 2+ without HER2 gene amplification), suggesting that breast cancer patients with low HER2 expression may also be selected for HER2-targeted therapy [31,34]. This evidence concerns the gene ERBB2 and breast cancer.